7 вынікі
Hyper immunoglobulin-E (IgE) syndrome is an autosomal immune deficiency disease. It is characterized by an increase in IgE and eosinophil count with both T-cell and B-cell malfunction. Here, we report an 8-year-old boy whose disease started with an unusual skin manifestation. When 6 months old he
BACKGROUND
Herein we report the first case of toxic epidermal necrolysis (TEN) occurring with use of vemurafenib.
METHODS
A 75-year-old female patient was being treated with vemurafenib for stage IV melanoma with BRAF V600E mutation. She suddenly presented fever, diffuse pruriginous maculopapular
Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the "still water" moves, now with multiple medications the patient survival can be improved. Dabrafenib is the second registered BRAF kinase inhibitor. In clinical trials it
BACKGROUND
Little has been reported on the costs of managing the adverse events (AEs) associated with current therapies for patients with regional or distant metastatic melanoma.
OBJECTIVE
To identify treatment-related AEs in patients with metastatic melanoma and to estimate the associated costs of
Dear Editor, Orf, also called contagious ecthyma, contagious pustular dermatitis, sore mouth, or scabby mouth, is a highly contagious zoonotic disease which is caused by a double-stranded DNA virus, ORFV (Parapoxvirus genus of the family Poxviridae) (1). The infection is endemic to sheep and goats,
Background: BRAFV600E mutation is present in a subset of pediatric brain tumors. Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAFV600E kinase. The goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology Consortium (PNOC)
BACKGROUND
Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17-22 weeks. We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain.
METHODS
We undertook a multicentre,